Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Idorsia Pharmaceutical Ltd (IDIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8217
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and systemic lupus erythematosus, fabry disease and acute coronary syndrome. It offers pipeline portfolio such as asthma and allergy disorders, anxiety, epilepsy, and cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage. Idorsias therapeutic expertise caters to the pathology requirements of cardiovascular disorders, orphan diseases, central nervous system disorders, immunological disorders, and others. The company works in collaboration with Janssen Biotech to develop and commercialize aprocitentan drug candidates to treat resistant hypertension; and with Reveragen to develop non-hormonal steroid modulator for treating duchenne muscular dystrophy. Idorsia is headquartered in Allschwil, Switzerland.

Idorsia Pharmaceutical Ltd (IDIA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Idorsia Enters into Research Agreement with Roche 10
Idorsia and Janssen Biotech to Enter into option Agreement 11
Licensing Agreements 12
Vaxxilon Enters into Licensing Agreement with Max-Planck Innovation 12
Equity Offering 13
Idorsia Raises USD308.2 Million in Private Placement of Shares 13
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 15
Debt Offering 16
Idorsia Raises USD202.1 Million in Private Placement of 0.75% Bonds Due 2024 16
Idorsia Pharmaceutical Ltd – Key Competitors 17
Idorsia Pharmaceutical Ltd – Key Employees 18
Idorsia Pharmaceutical Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Jul 24, 2018: Idorsia announces financial results for the first half 2018 20
Apr 19, 2018: Idorsia Announces Financial Results For First Quarter 2018 21
Feb 06, 2018: Idorsia announces financial results for 2017 – company off to a great start – 4 compounds to enter Phase 3 development 22
Oct 24, 2017: Idorsia announces financial results as of 30 September 2017 24
Aug 03, 2017: Idorsia announces half year results for 2017 – successful start of new biopharmaceutical company 25
Corporate Communications 27
Jun 16, 2017: Idorsia – Reaching out for more 27
Jun 09, 2017: Publication of Idorsia’s prospectus relating to the listing of Idorsia on SIX Swiss Exchange 28
Clinical Trials 30
Jun 11, 2018: Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia 30
Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Idorsia Pharmaceutical Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Idorsia Enters into Research Agreement with Roche 10
Idorsia and Janssen Biotech to Enter into option Agreement 11
Vaxxilon Enters into Licensing Agreement with Max-Planck Innovation 12
Idorsia Raises USD308.2 Million in Private Placement of Shares 13
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 15
Idorsia Raises USD202.1 Million in Private Placement of 0.75% Bonds Due 2024 16
Idorsia Pharmaceutical Ltd, Key Competitors 17
Idorsia Pharmaceutical Ltd, Key Employees 18
Idorsia Pharmaceutical Ltd, Subsidiaries 19

List of Figures
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Idorsia Pharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Australian Postal Corporation:企業の戦略的SWOT分析
    Australian Postal Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Luzhou Bio-chem Technology Limited:企業の戦略・SWOT・財務分析
    Luzhou Bio-chem Technology Limited - Strategy, SWOT and Corporate Finance Report Summary Luzhou Bio-chem Technology Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Waste Management, Inc.:企業の戦略・SWOT・財務情報
    Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • China Animal Husbandry Industry Co Ltd (600195):企業の財務・戦略的SWOT分析
    China Animal Husbandry Industry Co Ltd (600195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Bandai Namco Holdings Inc. (7832):企業の財務・戦略的SWOT分析
    Bandai Namco Holdings Inc. (7832) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • TH Heavy Engineering Berhad (THHEAVY):企業の財務・戦略的SWOT分析
    TH Heavy Engineering Berhad (THHEAVY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • I Grandi Viaggi Spa
    I Grandi Viaggi Spa - Strategy, SWOT and Corporate Finance Report Summary I Grandi Viaggi Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TransMontaigne Product Services LLC:企業の戦略的SWOT分析
    TransMontaigne Product Services LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Aeon Delight Co Ltd:企業の戦略・SWOT・財務情報
    Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pharming Group NV (PHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for …
  • GenapSys Inc:医療機器:M&Aディール及び事業提携情報
    Summary GenapSys Inc (GenapSys) is engaged in the development of DNA sequencing technologies for applied genomic testing, and medical sequencing. The company offers a Gene Electronic Nano-Integrated Ultra-Sensitive (GENIUS) technology platform that identifies the genome and delivers the insights of …
  • Sumitomo Dainippon Pharma Co Ltd (4506):製薬・医療:M&Aディール及び事業提携情報
    Summary Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, …
  • Lidds AB (LIDDS):製薬・医療:M&Aディール及び事業提携情報
    Summary Lidds AB (Lidds) is a developer of pharmaceutical products for the treatment of cancer and other diseases. The company offers Liproca Depot, an injectable product used for the treatment of prostate cancer. Its Liproca is a bioresorbable, biocompatible and locally injectable modified release …
  • Neuwave Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary NeuWave Medical Inc (NeuWave Medical), a subsidiary of Ethicon US LLC is a medical device company that develops and commercializes energy-based minimally invasive medical devices. The company’s product Certus 140 microwave ablation (coagulation) system is a minimally invasive soft tissue abl …
  • TC Pipelines LP (TCP):企業の財務・戦略的SWOT分析
    Summary TC Pipelines LP (TC Pipelines) operates as an oil and gas company that manages natural gas pipelines and related assets. It offers development and operation of North American energy infrastructure including natural gas and liquids pipelines, power generation and gas storage facilities. It op …
  • Energy Absolute Public Co Ltd (EA):企業の財務・戦略的SWOT分析
    Summary Energy Absolute Public Co Ltd (Energy Absolute), formerly Suntech Palm Oil Ltd, is a renewable energy service provider that offers opportunities for networking, education and business creation. The company offers products such as biodiesel and glycerin. It offers services such as dry washing …
  • Staples, Inc.:企業の戦略・SWOT・財務情報
    Staples, Inc. - Strategy, SWOT and Corporate Finance Report Summary Staples, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Dr. Reddy’s Laboratories Limited:企業の戦略・SWOT・財務情報
    Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report Summary Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • ASIT Biotech SA (ASIT):企業の財務・戦略的SWOT分析
    Summary ASIT Biotech SA (ASIT Biotech), formerly BioTech Tools SA is a clinical stage biopharmaceutical company that develops in-vitro and in-vivo biotech tools. The company develops and commercializes immunotherapy medicines for respiratory and food allergies using ASIT plus technology platform. It …
  • Cargill, Incorporated:企業のM&A・事業提携・投資動向
    Cargill, Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cargill, Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆